Merck & Co, Inc. (NYSE: MRK) is planning to buy all the outstanding shares of OncoImmune for an upfront payment of $425 million in cash. Additionally, the shareholders of OncoImmune will be able to get the sales-based payment upon successfully achieving set targets. OncoImmune